Infectious Diseases

“We started out 2025 with an environment that was rife with myths and disinformation," said Robert H. Hopkins, Jr., MD, in this year-end recap of 2025 and the pediatric vaccine landscape.

Climate lag time poses urgent health risks for children, necessitating proactive pediatric care and policy changes to address future climate-related challenges.

See the full case of our most recent puzzler quiz, and view the correct diagnosis of this 19-year-old female with painful, purpuric nodules in the phalanges of her fingers

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on the recently updated ACIP recommendation on the hepatitis B vaccine.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 pounds.

Phase 3 results show oral zoliflodacin was noninferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

According to multiple reports, the FDA is investigating the safety of a pair of already-approved protective treatments for respiratory syncytial virus.

“We took a different approach by looking at colonizing bacteria, and we found vaccination reduced antimicrobial resistance through a completely different mechanism," said Brooke Ramay, lead author of the study.

State repeals of nonmedical vaccine exemptions were linked to higher kindergarten vaccination rates, with minimal substitution toward medical exemptions.

The ACIP committee voted to pass both resolutions to update its recommendation on the hepatitis B vaccine for infants.

"For those not receiving the HBV birth dose, it is suggested that the initial dose is administered no earlier than 2 months of age," reads part of vote 1.

New US modeling study results find nirsevimab would avert the most infant RSV-LRTD events and hospitalizations compared with clesrovimab or RSVpreF maternal vaccination.

A national poll shows many parents plan in-person Thanksgiving gatherings despite concerns about COVID-19 transmission and risks to high-risk relatives.

The CDC website now claims "studies supporting a link [between vaccines and autism] have been ignored by health authorities."

In this Q&A, nurse practitioner Tracey Gaslin, PhD, discusses tick bites in pediatric patients, from how to prevent a bite to what to do after a bite, and highlights resources available from the Fight the Bite initiative.

Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.

In this brief clip, Lori Handy, MD, MSCE, of CHOP, explains the evolving dynamic of trust between patients, parents, and health care.

Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

Yohei Doi, MD, IDWeek chair, Infectious Diseases Society of America, provides some insights on the happenings at this year’s event from Atlanta, Georgia.

* Generic lenacapavir could be produced for $25 per person per year at scale, according to an analysis presented at IDWeek 2025 in Atlanta.